Overall survival. (A) By CML phase from the time of T315I mutation detection. (B) Patients with T315I mutation versus P-loop mutations versus non–P-loop mutations versus no mutation from the time of imatinib failure. (C) Patients with T315I mutation versus P-loop mutation versus non–P-loop mutation from the time of mutation's detection.